Intervention

ZG006

ClinicalTrials.gov intervention label

Clinical trials8

Recruiting7

Common conditions5

Lead sponsors shown1

Clinical trials

8 shown

Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung CancerNCT07231445 · 2026-04-21

Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung CancerNCT07189455 · 2025-12-12

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaNCT07038096 · 2025-09-23

A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung CancerNCT06592638 · 2025-03-31

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung CancerNCT06283719 · 2024-09-02

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.NCT06440057 · 2024-08-29

Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaNCT05978284 · 2023-10-27

Study of ZG006 in Participants With Neuroendocrine Prostate CancerNCT07024277 · 2025-08-01

NOT_YET_RECRUITING

Common conditions

Small Cell Lung Cancer5 Neuroendocrine Carcinoma3 Neuroendocrine Cancer1 Neuroendocrine Prostate Cancer1 Small-cell Lung Cancer1

Leading sponsors

Suzhou Zelgen Biopharmaceuticals Co.,Ltd8

Trial status mix

RECRUITING7

NOT_YET_RECRUITING1

Phase mix

PHASE16

PHASE25

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.